

Barcelona, June 19th 2017

SIGNIFICANT EVENT

Almirall ready to react to introduction of generic to Acticlate™ in the US market

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

In response to the US launch of doxycycline hyclate in tablets, a generic competitor to Acticlate™, it is ready with an Authorized Generic (AG) of Acticlate™ to be introduced to the US market.

Additionally, Aqua, an Almirall company, has approval to commercialise a new and market-exclusive line extension for Acticlate™ that would offer HCPs and patients a valuable option in the oral treatment of Acne.

Almirall will closely monitor the impact of the new market entrant in the coming weeks. According to **Alfonso Ugarte, Executive Vice President, Global Commercial Strategy**: *“Even though we did not know the exact timing, we had been anticipating generic competition to Acticlate™. It is because of this that we are ready to react and will work with HCPs to continue to offer solutions in the oral acne space. We will soon provide an update on the related impact of this new situation. This update will come no later than our Q2 results teleconference, scheduled for 24th July 2017. With the action plans that we have in place, we expect to mitigate the potential decline of our market share”.*

Yours sincerely,

Pablo Divasson del Fraile
Corporate Comms. & Investor Relations Department
investors@almirall.com